Aurobindo Pharma gains approval for Darunavir tablets, shares up
Aurobindo achieved a total of 500 ANDA approvals from the USFDA, including 478 Final approvals and 22 tentative approvals29-11-2023
29-11-2023
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Received US FDA approval for Darunavir Tablets, 600 mg and 800 mg29-11-2023
AUROBINDO PHARMA LTD. - 524804 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificates28-11-2023
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Newspaper Publication
News Paper publication of Postal Ballot25-11-2023
AUROBINDO PHARMA LTD. - 524804 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificates24-11-2023
AUROBINDO PHARMA LTD. - 524804 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Notice of Postal Ballot dated 9th November 2023 is enclosed.24-11-2023
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Acquisition
Incorporation of a new wholly owned subsidiary, Auro Trading Private Limited.22-11-2023
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
Completion of purchase of shares of Theranym Biologics Private Limited by the Company from Curateq Biologics Private Limited, both wholly owned subsidiary companies.22-11-2023
AUROBINDO PHARMA LTD. - 524804 - Completion Of Purchase Of Shares Of Theranym Biologics Private Limited
Completion of purchase of shares of Theranym Biologics Private Limited by the Company from Curateq Biologics Private Limited, both wholly owned subsidiary companies22-11-2023
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release - Evive Biotech and Acrotech Biopharma announce US FDA approval for Ryzneuta for CIN22-11-2023